It is important to gain an understanding of the pharmacological activities of metabolite (s) of compounds in development, especially if they are found in systemic circulation in humans. Pharmacological evaluation of metabolites is normally conducted with synthetic standards which become available during various stages of drug development. However, the synthesis of metabolite standards may be protracted, taking anywhere from several weeks to months to be completed. This often slows down early pharmacological evaluation of metabolites. Once a metabolite(s) is found to possess comparable (or greater) pharmacological activity than the parent compound, additional studies are carried out to better understand the implications of circulating pharmacologically active metabolite(s). To conduct some of these studies as early as possible without slowing the progression of a compound in development is important, especially if critical go or no-go decisions impinge on the outcomes from these studies. An early pharmacological evaluation of significant metabolites is hereby proposed to be conducted in the drug discovery stage so that all pertinent studies and information can be gathered in a timely manner for decision-making. It is suggested that these major metabolites be isolated, either from biological or chemical sources, and quantified appropriately. In the case of biologically generated metabolites, NMR is proposed as the tool of choice to quantitate these metabolites prior to their evaluation in pharmacological assays. For metabolites that have the same UV characteristics as the parent compound, quantitation can be conducted using UV spectroscopy instead of NMR. In this paper, we propose a strategy that could be used to determine the pharmacological activities of metabolites isolated in sub-milligram quantities.
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INTRODUCTION
Pharmacological evaluation of new chemical entities is traditionally performed in early drug discovery. Enzyme and cell-based assays are often used to initially assess the potential pharmacological activities of compounds prior to further evaluation in animal models. Frequently, the relationship between the structure and pharmacological activity is further studied by chemically synthesizing close structural analogues with the intention of optimizing drug-receptor interaction for improved potency. This SAR work is critical during the lead optimization phase of new potential therapeutic agents as modifications of chemical templates can also lead to significant alterations in physico-chemical properties, which in turn can dramatically influence the ADME characteristics of compounds.
Significant chemistry effort is made in the lead optimization stage to generate compounds with desired pharmacological and ADME properties. An alternative, yet less exploited way of creating close analogues from a pharmacologically active template is through biological means, such as enzyme-mediated metabolism or microbial conversion.
During early drug discovery studies, metabolic modifications of chemical templates by various sub-cellular and cellular systems from different animal species are routinely investigated. Metabolite profiles, which are often obtained by combination of liquid chromatography, mass spectrometry and ultraviolet spectroscopy (LC/MS/UV), identify new chemical entities produced by these biological enzymes. However, because of the low levels of these metabolites, further pharmacological evaluations of these compounds have not routinely been performed in the past.
Metabolic conversion has not traditionally been considered as a source of generating new chemical entities for further pharmacological evaluation. In addition to regarding metabolites merely as excretory products, there are several other reasons why medicinal chemists have not considered metabolites as potential drug candidates. In the past, elucidating the structures of these metabolites was a challenge. Providing a list of hypothetical structures based on inconclusive mass spectral data was one of the reasons for lack of interest in these metabolites by the medicinal chemists and biologists. This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 15, 2010 as DOI: 10.1124 at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from However, with advancements in mass spectrometry and NMR techniques, it has become a routine practice to obtain structures of metabolites in early discovery (Mutlib and Shockcor, 2003) . A significant hurdle in the past has been the inability to isolate sufficient quantities of metabolites in relatively pure form for further evaluation.
Recently, it has become easier to produce sufficient amounts of metabolites using any of the various biological or biomimetic systems. It has been shown that these biological systems can be used reliably to generate metabolites in the microgram to milligram range.
Despite the ability to generate and isolate sufficient quantities of pure samples of metabolites, the challenge has been to obtain an accurate weight of the compounds for proper evaluation in pharmacological assays.
A strategy advocating the use of NMR as a quantitative tool to determine the concentrations of biologically synthesized metabolites has been discussed in the literature and elsewhere (Espina et al., 2009) . Traditionally, biologically isolated metabolites have not been considered as a source of generating reference standards for further quantitative work. However, because of the FDA guidance on safety testing of metabolites, some laboratories have contemplated using these biologically synthesized metabolites as "reference standards" for preliminary quantitative studies. 1 H NMR has been proposed as the method of choice in authenticating and quantitating these biologically synthesized metabolites prior to their further use as standards in more sensitive LC/MS based quantitative assays (Vishwanathan et al., 2009) . We have successfully used this approach to obtain metabolite concentrations and exposure values using sample pooling methods (Vishwanathan et al., 2009) . A secondary consequence of being able to obtain accurate weights of isolated metabolites is further evaluation of their pharmacological activities.
Once the exact structure and concentration of the isolated metabolite is known, it can be submitted to pharmacologists for further testing in enzyme-and cell-based assays. In this paper, we describe a strategy that was used to effectively elucidate the structure and determine the concentrations of metabolites prior to evaluation of pharmacological activities of these biologically generated compounds. A compound which was found to be highly metabolized by human liver microsomes (see Figure 1 ), was studied extensively along with its major metabolite(s) in animals to better understand their This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS
Chemicals and Supplies
Compound 1 (see Figure 1) Solvents used for chromatographic analysis were HPLC or ACS reagent grade and were purchased from EMD Chemicals (Gibbstown, NJ). All deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). All general solvents and reagents were the highest grade available commercially.
In Vitro Incubations and Isolation of Metabolites for NMR Characterization and Quantitation
A large-scale incubation of compound 1, at a concentration of 0.02 mM, with human liver microsomes was conducted to generate metabolite M1 (see Figure 1) . A total of 50 x 2 mL incubations were conducted in 0.1 M potassium phosphate buffer (pH 7.4), containing 1 mg/mL microsomal protein, 5 mM NADPH, and 8 mM MgCl 2 at 37° C for 60 min. Protein precipitation was conducted using 4 mL of 2% formic acid in acetonitrile per incubation. The tubes were vortexed for 1 min and centrifuged at 2400 x g for 10 minutes at 4° C. The supernatants were transferred to clean culture tubes after which the organic phase was removed under a stream of nitrogen at 30 ºC. The aqueous phase from each tube was pooled and subjected to a cleanup on solid phase C 18 extraction cartridges.
This article has not been copyedited and formatted. The final version may differ from this version. The wash fractions were analyzed by injecting 50 μL of samples on a Thermo LTQ ion trap mass spectrometer and were found to be void of both compound 1 and M1. Elution of M1 was done using 25 mL aliquots of solvent varying in concentrations of acetonitrile in water (10%-100% acetonitrile; with 10% stepwise increase). Aliquots (50 μL) of each fraction were injected on the Thermo LTQ mass spectrometer; M1 was found to elute completely in the 30%, 40% and 50% fractions. These fractions were pooled (75 mL total) and subsequently reduced in volume to ~ 4 mL which was subjected to further purification on an Agilent 1100 HPLC system equipped with a fraction collector.
Aliquots (500 μL) of the sample were injected on a Varian Pursuit C 18 (250 x 10 mm, 5 μm) semi-preparative column coupled to the HPLC system. The mobile phase consisted of (A): 0.1% formic acid in H 2 O and (B): acetonitrile which was delivered at 5 mL/min.
The gradient consisted of increasing the % organic (B) from the initial value of 25% to 50% in 7 min followed by a linear ramp to 95% B in one minute before re-equilibrating the column. Compound-related components were monitored using a UV detector set at 300 nm. Fractions containing M1 were pooled and lyophilized. Approximately 1 mg of M1 was isolated as its formate salt in >95% purity as determined by LC/ UV/MS and NMR analysis. The isolated metabolite was handled in a glove box to minimize contamination with water prior to NMR analysis.
In Vitro Metabolism of Metabolites M1a-1 and M1a-2 (Enantiomers of M1)
Metabolites M1a-1 and M1a-2 (see Figure 2 ), chemically synthesized enantiomers of M1, were incubated with male Sprague-Dawley rat, male cynomolgus monkey and male human liver microsomes (1 mg/mL) fortified with cytosol (2 mg/mL) in the presence of NADPH (5 mM), MgCl 2 (8 mM), GSH (2 mM) and UDPGA (2 mM) in a total volume of 1 mL (adjusted with 0.1 M phosphate buffer, pH 7.4) at 37° C for 60 minutes. Protein
This article has not been copyedited and formatted. The final version may differ from this version. Luna column (150 x 2.1 mm) using acetonitrile and 5 mM ammonium acetate as the mobile phase. The composition of the mobile phase was changed from 10% acetonitrile to 40% in the first 18 minutes after which the column was washed with 95% acetonitrile for 5 minutes. Subsequently the column was re-equilibrated with 10% acetonitrile prior to the next injection. Deuterated water (5 mM ammonium acetate) was substituted in LC/MS experiments designed to determine the number of exchangeable protons in metabolite M1. The flow rate was set at 200 μL/min. Mass spectral data was obtained with a LTQ Orbitrap mass spectrometer (Thermo Scientific, San Jose, CA) which was equipped with an electrospray ionization source and operated in the positive ionization mode with the electrospray needle kept at +4500 kV. Settings for the mass spectrometer were optimized to provide a structurally relevant range of product ions from MS/MS (under high energy collisional dissociated mode) and MS n (ion trap mode) experiments.
The capillary temperature and voltage were set at 370 ºC and 29 V, respectively.
Ultrapure nitrogen was used as the nebulizer gas and curtain gas. The relative collision Figure 2) , were injected onto the LC/MS to compare the retention times and mass spectral fragmentation patterns. Chiral separation of M1a-1 and M1a-2 was conducted as described previously (Chen et al., 2010 ). An aliquot of M1 was injected on the same chiral column to compare the retention time of this metabolite with the HPLC separated enantiomers, M1a-1 and M1a-2. It was found that M1a-1 and M1a-2 had retention times of 10.2 and 13.4 min, respectively. Metabolite M1 showed identical retention time as M1a-1 (see Chen et al, 2010) .
LC/MS Analysis of Microsomal and Rat Plasma Extracts:
The microsomal and plasma extracts were subjected to LC/MS analysis using the same experimental conditions as described above.
Quantitative LC/MS Analysis of Plasma Samples from Pharmacokinetic Studies:
Compound 1, M1a-1 and M1a-2 were quantified in male rat plasma utilizing a non-validated LC/MS/MS assay. The assay limit of quantification was 1 ng/mL using 50 μ L aliquots of rat plasma. The standard curve ranged from 1 to 1000 ng/mL for all compounds. All samples, when needed, were appropriately diluted. 
NMR Spectroscopy
NMR Instrument: NMR data were recorded at 30ºC on a 600 MHz Bruker Avance III spectrometer with a 5 mm CPTCI CryoProbe™ (Bruker BioSpin Corporation, Billerica, MA) at the basic frequency of 600.13 MHz. The spectrometer was controlled using TopSpin ® (Bruker BioSpin, v 2.1 pl 1). All data collection was performed without spinning the samples. The probe was tuned and matched to the specific frequency using This article has not been copyedited and formatted. The final version may differ from this version. 
Quantitative NMR Analysis of Metabolite M1:
The quantitative NMR technique used in this study was similar to what has been described previously (Espina et al., 2009) .
Briefly, each sample was dissolved in the same volume (500 μL) of the solvent and was placed in the magnet at the same depth. Each proton spectrum was acquired with 65,536 data points over a 12, 019 Hz spectral window using a 90º (8.3 μs) pulse and the gradient 1D nuclear Ovehauser effect spectroscopy (NOESY) presat pulse sequence (ACD/Labs, Inc, v 11.0). The FID Reconstruction method was applied to the full spectrum during automatic baseline correction prior to integration. All the spectra in a series (absolute intensity) were combined using the SpecManager Series command.
Integration of the spectra in a series was performed manually using group treatment within SpecManager. For quantitation purposes, integration of all aromatic protons (δ 8.37, 8.30, 7.55, and 7 .44) of compound 1 was used to generate calibration curve as described previously (Espina et al., 2009 ). An average of the normalized integral value for compound 1 was plotted against the concentration values to create a calibration curve as described before (Espina et al., 2009 ). The table of common integrals for the series was transferred to Microsoft Excel for analysis. All samples were analyzed by NMR in triplicates (three separate determinations of the same sample on different occasions). The concentrations of quality control (QC) samples and metabolite M1 were obtained using the calibration curve generated from compound 1. All spectra were referenced to the residual solvent signal.
Pharmacological Evaluation of Metabolite M1
Using NMR, the exact concentration of the isolated metabolite was measured using the calibration curve constructed with the compound 1 as described previously by Espina et al (2009) . Briefly, the NMR spectra of the parent compound were obtained at 5 different concentrations and a calibration curve created based on the integration of aromatic proton signals (average). The concentration of metabolite M1 was calculated using the standard curve as described previously (Espina et al., 2009) . Another metabolite of compound 1, available as a synthetic standard, was used as a quality control to ensure that the NMR quantitation was verified by gravimetric determination. The results are presented in samples that were used for measuring the binding and functional potency of the isolated metabolite on the target receptors. In the same study, a solution of compound 1 was prepared at a similar concentration as the isolated metabolite M1. The concentrations of both samples were confirmed by quantitative NMR before being simultaneously evaluated in the pharmacological assays. Upon the availability of the synthetic standards of metabolite M1, pharmacological evaluations were conducted using solutions prepared from compounds which were weighed accurately using analytical balances. The pharmacological activities of various compounds, including that of the isolated metabolite M1, are shown in Table 2 .
Pharmacokinetics of Compound 1, M1a-1 and M1a-2
Single dose IV (2 mg/kg) studies were conducted in male Sprague-Dawley rats with compounds 1, M1a-1 and M1a-2 (pure enantiomers).
Male Sprague-Dawley rats (n=3 per dose group) were purchased from Charles River (Raleigh, NC) and acclimated in an IACUC accredited facility for a few days prior to dosing. Animals used in the study were surgically cannulated for jugular and femoral veins by the vendor. The compounds were formulated in 5% dextrose and 0.5% lactic acid, pH 3.5 for intravenous administration. The IV dose volume was 1 mL/kg. The compound was administered to animals that had access to food and water ad libitum. 
Pharmacokinetic Analysis
The pharmacokinetic parameters for individual animals were determined using a non-compartmental analysis module (Model 201) of the pharmacokinetic software package WinNonlin, ver. 5.1 (Pharsight, CA). The program applies a model-independent approach and the standard methods described previously (Gibaldi and Perrier, 1975) .
The systemic clearance (CL T ) was calculated as Dose/AUC 0-∞ , and volume of distribution at steady-state (Vd ss ) was calculated as MRT•CL T , where MRT is AUMC 0-∞ /AUC 0-∞ .
The area under the plasma concentration versus time curve (AUC) was calculated using the linear trapezoidal method. Where warranted, the slope of the apparent terminal phase was estimated by log-linear regression using at least 3 data points and the terminal rate constant (λ) was derived from the slope. AUC 0-∞ was estimated as the sum of the AUC 0-t (where t is the time of the last measurable concentration) and C t /λ. The apparent terminal half-life (t 1/2 ) was calculated as 0.693/λ. For pharmacokinetic calculations, all drug concentration values below the assay limit of quantification (BLQ) were treated as zero.
Statistics
A least-squares linear regression analysis of the UV peak areas versus concentrations of 
RESULTS
Identification and Characterization of Metabolite M1
The in vitro metabolism studies conducted with compound 1 showed that it was primarily converted to a single metabolite ( M1a-1 and M1a-2 were both relatively stable in rat liver microsomes, producing only a single hydroxylated metabolite (Figure 6a ). However, interestingly, M1a-2, was found to be extensively metabolized by monkey and human liver microsomes to a single hydroxylated metabolite (complete structure not determined). In contrast M1a-1 was found to be relatively stable in the presence of monkey and human liver microsomes (Figure 6b ).
Quantitation of Biologically Generated Metabolite M1
Metabolite M1 was produced in sufficient quantities by human liver microsomes to be characterized and quantitated by NMR analysis. The quantitation of M1 was conducted using the method as described previously (Espina et al. 2009 ). The concentration of M1 was determined to be 1.72 mM (see Table 1 ). A quality control (QC) sample (another synthetic metabolite standard of compound 1) was used during the NMR analysis to This article has not been copyedited and formatted. The final version may differ from this version. For M1, the isolated material showed low nM binding and affinity to the receptor, that was equivalent to that of the parent compound. This initial evaluation using the isolated material was later confirmed by testing the corresponding correct enantiomer which had similar in vitro binding as was previously obtained using the isolated material (see Table   2 ). Interestingly, the epimeric form (M1a-2) of this metabolite was approximately two times less active than M1a-1 in three out of four pharmacological assays (Table 2) .
However, it appears that an introduction of a hydroxyl group did not alter the pharmacological activity significantly as compared to the parent compound.
In Vivo Pharmacokinetics of Compound 1, M1a-1 and M1a-2
Figures 7a-c illustrates semilogarithmic plasma concentration-time profiles for compounds 1, M1a-1 and M1a-2 after 2 mg/kg intravenous bolus doses. The concentration-time profiles were best described by one-compartment models with firstorder elimination rate constants. Pharmacokinetic parameters were characterized by high clearance compared to liver blood flow, moderate volume of distribution compared to plasma volume and short elimination half-lives (see Table 3 ). Both metabolites had similar clearance and volume of distribution. Oral administration of the compounds (10 mg/kg) produced non-detectable levels of the compound and hence the data are not shown in this report.
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
NMR has traditionally been used to elucidate structures of small and large molecules (Prestgard, 2001; Mutlib and Shockcor, 2003) . NMR, especially in combination with mass spectrometry and other hyphenated techniques, is customarily used to fully elucidate structures of previously uncharacterized metabolites (Mutlib and Shockcor, 2003) . We have demonstrated that NMR could be utilized to quantitate metabolites isolated from biological sources (Espina et al., 2009) . In that study it was shown that the compounds, from which the metabolites are derived, could be used to create calibration curves for quantitative analysis. This approach was successfully used to obtain exposure values of metabolites present in plasma of preclinical species, hence circumventing the need for synthetic standards of metabolites or radiolabeled studies. Recently, we showed the This article has not been copyedited and formatted. The final version may differ from this version. derived metabolites, a series of studies based on initial results, were conducted with compound 1 and its synthesized metabolite standards. The purpose of these was to demonstrate some of the outcomes and impact of conducting early metabolite identification and quantitation in discovery. The cascade of studies that may occur as a result of confirmatory metabolite identification and quantitation are described in this paper (see Scheme 1).
Compound 1 was found to be metabolized to a major single hydroxylated metabolite by human liver microsomes. As shown in Figure 1 , the hydroxylation took place on a prochiral center leading to the possibility of several isomers. While the position of hydroxylation was easily determined by initial NMR analysis of the isolated metabolite, the exact stereochemistry could only be resolved by conducting synthesis and chiral HPLC separation of enantiomers (Chen et al., 2010) . After the identity of the metabolite was unequivocally confirmed by HPLC and mass spectral comparisons with synthetic standards, additional studies such as pharmacological and pharmacokinetic evaluations were conducted. It is important to note that it was close to 12 months (from the time the position of hydroxylation on M1 was determined) before synthetic standards of this metabolite were available for pharmacological evaluations. In contrast, it took 3-4 weeks from the time the major hydroxylated metabolite was initially identified in human liver microsomes before pharmacological evaluation of the isolated metabolite was conducted.
The protracted time required to obtain the synthetic standard of this metabolite was due to a number of reasons including complex synthesis needed to achieve the desired stereospecificity. While the initial pharmacological tests on the isolated metabolite were considered reliable and accurate, it was important to demonstrate (as part of the verification process) that the synthetic standard produced similar or identical results as the isolated metabolite in pharmacological evaluations (see Table 2 ). Indeed, the results were very similar and hence confirmed the value of conducting quantitative NMR on isolated metabolites so that pharmacological assessments could be made earlier with such isolated metabolites rather than waiting for synthetic standards of metabolites.
Interestingly, the introduction of hydroxyl group on the bridged morpholine ring system did not diminish the pharmacological activity of the metabolite M1. This information This article has not been copyedited and formatted. The final version may differ from this version. was useful to chemists as this led to design of other molecules with modified bicyclic ring system (Chen et al., 2010) . Fluorinated analogues were also considered so that the formation of the hydroxylated metabolite could be mitigated. By evaluating the pharmacological activities of metabolites, one may also gain an insight into structureactivity (SAR) relationship; hence potentially influencing the design of newer molecules (see Scheme 1) . For example, in the case of compound 1, fluorine and methyl groups were substituted in the metabolic soft spot, realizing that an introduction of a small group at that position was not going to compromise the pharmacological activity. Further studies with these analogues are in progress. Often the chemical synthesis of metabolite(s) is accelerated once it is realized that it possesses pharmacological activity (see Scheme 1) . This in turn allows additional testing of the metabolite in a pharmacology model. Other studies such as in vitro metabolic disposition or in vivo pharmacokinetic evaluation of these synthetic metabolite standards could then easily be conducted. The information derived from all these studies can lead to better understanding of the disposition of the parent compound as well its pharmacologically active metabolite in preclinical species. In some cases, the properties of metabolite (or other synthesized) analogues may be more favorable than the parent compound; hence potentially creating a new drug candidate. With compound 1, it was found that the major metabolite M1 was produced in a very stereospecific manner, existing as the enantiomer M1a-1. Furthermore, it was shown that this enantiomer was more metabolically stable than M1a-2, which was shown not to be produced as a metabolite. The racemic mixture (M1a) also displayed liver microsomal instability due to the rapid metabolism of enantiomer, M1a-2. If this hydroxylated metabolite was further pursued as a potential drug candidate, it would be desirable to synthesize the more stable enantiomer, M1a-1.
The significant difference in the metabolic disposition of the two enantiomers is
consistent with what has been reported before for other racemic compounds (Mutlib and Nelson, 1997 and literature cited therin).
Pharmacokinetic studies showed that metabolite M1 (M1a-1 enantiomer) had higher clearance and lower exposure values as compared to the parent compound 1. The overall pharmacokinetic behavior of two enantiomers, M1a-1 and M1a-2 were similar. This
This article has not been copyedited and formatted. The final version may differ from this version. observation was consistent with in vitro metabolism data that showed similar metabolic stability in the presence of rat liver microsomes. Furthermore, the in vitro metabolism data suggested that these hydroxylated metabolites (M1a-1 and M1a-2) were not predisposed to glucuronidation as evidenced by lack of glucuronide conjugates in the metabolite profile (Figure 6a) . Furthermore, the LC/MS analysis of plasma extracts obtained from the pharmacokinetic studies showed an absence of any glucuronide conjugates, consistent with in vitro metabolism data (data not shown). It is postulated that the high clearance of M1a-1 and M1a-2 could be due to their rapid elimination in bile, though further studies will be needed to confirm this. The high clearance of this metabolite (M1a-1) observed in rats led to termination of this compound as a viable candidate for further development.
A strategy is proposed to ensure that reliable pharmacology results are obtained from metabolites that are isolated from biological sources (see Scheme 2). Once a metabolite of interest is selected, it is proposed that a scale-up and subsequent isolation and characterization take place to confirm the structure of the metabolite. The NMR analysis of the isolated metabolite is used to confirm the identity (and also purity) of the isolated metabolite. Subsequently, the metabolite can be quantitated by HPLC/UV if the absorption characteristics of the metabolite and the parent compound are considered to be similar. Usually, if the site of metabolism is remote from the UV chromophore, the absorption characteristics are relatively same for the parent compound and its metabolite(s). If the metabolite UV spectrum is not the same as the parent compound, 1 H-NMR can be used to generate the calibration curve for quantitation purposes (Espina acts as a quality control for both NMR analysis and also for pharmacological evaluation.
This article has not been copyedited and formatted. The final version may differ from this version. Alternatively, to ensure the integrity of the results, an analogue of the parent compound or synthetically available metabolite standard, could be weighed and its concentration verified by NMR so that pharmacological evaluations could be performed (Table 1 ). In the case of compound 1, a synthetic standard of metabolite that was used as the QC for quantitative NMR was found to be inactive (data not shown).
The value of performing quantitative NMR on isolated metabolites for the purpose of further pharmacological tests was demonstrated. A better understanding of the disposition of compound 1 and its metabolite M1 was achieved once it was demonstrated that M1 was pharmacologically active. Because sufficient quantities of M1 were readily available for quantitation as well as for method development, the synthesis and identification of correct enantiomer was greatly facilitated. Subsequent pharmacokinetic evaluations of the pharmacologically active chemically synthesized metabolite showed that it had the propensity to be rapidly cleared in vivo, making it an unlikely candidate for further development. Overall, as illustrated with this example, design of experiments and critical resource-sparing decisions could be facilitated if pharmacological activities of metabolites are known much earlier in the drug discovery and development process.
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